Scholar Rock Holding Corporation
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- David L. Hallal
- Full Time Employees
- 289
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 301 Binney Street Cambridge MA United States 02142
- IPO Date
- May 24, 2018
- CIK
- 0001727196
- Website
- scholarrock.com
- Similar Companies
- Business
- Scholar Rock Holding Corporation (SRRK) is a Cambridge, Massachusetts-based biopharmaceutical company founded in 2012 that discovers, develops and delivers selective inhibitors targeting the transforming growth factor beta (TGFβ) superfamily of protein growth factors for serious diseases where growth factors play a fundamental role; its investigational product candidates include apitegromab (SRK-015), a selective inhibitor of myostatin activation in phase 3 clinical trials for spinal muscular atrophy in combination with standard therapies, SRK-181, a TGFβ1 inhibitor that has completed phase 1 trials for cancers resistant to checkpoint inhibitors such as anti-PD-1 or anti-PD-L1 therapies, and SRK-439, a myostatin inhibitor in development for cardiometabolic disorders. The company advances therapies across neuromuscular disorders including spinal muscular atrophy and Duchenne muscular dystrophy, cardiometabolic disorders, cancer, fibrosis, iron-restricted anemia, idiopathic pulmonary fibrosis and amyotrophic lateral sclerosis, with operations focused in the United States from its headquarters at 301 Binney Street, Cambridge, Massachusetts. In recent developments, Scholar Rock completed topline data readouts from phase 3 trials of apitegromab positioning it for U.S. biologics license application and European marketing authorization application submissions in the first quarter of 2025 and potential U.S. commercial launch in the fourth quarter of 2025; it bolstered its balance sheet with an upsized $345 million follow-on equity offering providing pro forma cash of approximately $463 million as of September 30, 2024; institutional investors including Vanguard Group and Redmile Group significantly expanded stakes in 2024; and the company presented at the Citi Annual Global Healthcare Conference in December 2025 while reporting an update on a third-party manufacturing site in October 2025.
Company News
Scholar Rock to Report Third Quarter 2026 Financial Results on November 10, 2026
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)
Scholar Rock (NASDAQ:SRRK) Stock Falls 5.1% – Here’s What Happened
Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law Firm
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Scholar Rock Holding Corporation $SRRK Shares Bought by Engineers Gate Manager LP
Scholar Rock: Reiterating 'Strong Buy' On FDA Approval SMA And Expansions Now In Play
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Autodesk, Eli Lilly, Etsy, Lear, Netskope, Nokia, Northrop Grumman, Rapid7, Rivian Automotive, Ulta Beauty, and More
Scholar Rock Holding Corporation (SRRK) Discusses FDA Approval and Clinical Impact of ISEMBYLD in SMA Treatment Transcript
Scholar Rock Marks 'Defining Moment' with First Muscle-Targeted Treatment for Spinal Muscular Atrophy
Scholar Rock prices first drug to target SMA muscle loss at $11,659 per vial
Why Scholar Rock Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)
US FDA approves Scholar Rock's muscle weakness drug
Scholar Rock Holding Corporation (SRRK) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Scholar Rock: Manufacturing Noise Obscures A Muscle-Targeted Franchise
Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (FSHD) Program as Participant Dosing Commences in Phase 2 FORGE Trial
Beaconlight Capital LLC Makes New Investment in Scholar Rock Holding Corporation $SRRK
9,494,084 Shares in Scholar Rock Holding Corporation $SRRK Purchased by BlackRock Inc.